Table 2. Main characteristics of clinical trials of targeted drugs in SCLC.
| ClinicalTrials.gov identifier | Design | Patient | Therapy | Status |
|---|---|---|---|---|
| NCT01286987 (128) | Phase 1, SA, OL | Relapsed SCLC | Talazoparib | Completed |
| NCT02289690 (129) | Phase 1/2, RCT, SA, OL | Untreated ED-SCLC | Arm 1: Veliparib + EC | Completed |
| Arm 2: Placebo + EC | ||||
| NCT01642251 (ECOG-ACRIN 2511) (130) | Phase 1/2, RCT, DB, PA | Untreated ED-SCLC | Arm 1: Veliparib + EC1 | Completed |
| Arm 2: Placebo + EC1 | ||||
| NCT01638546 (131) | Phase 2, RCT, DB, PA, Multicenter | Relapsed/refractory SCLC | Arm 1: Veliparib + Temozolomide | Completed |
| Arm 2: Placebo + Temozolomide | ||||
| NCT04334941 | Phase 2, RCT, OL, PA | SLFN11 positive ED-SCLC | Arm 1: Atezolizumab | Ongoing |
| Arm 2: Atezolizumab + Talazoparib | ||||
| NCT02511795 | Phase 1b, PA, OL, NR | Relapsed SCLC | AZD1775 + Olaparib | Completed |
| NCT03516084 | Phase 3, RCT, PA, OL, DB, Multicenter | ED-SCLC | Arm 1: Niraparib | Ongoing |
| Arm 2: Placebo | ||||
| NCT03009682 (SUKSES-B) | Phase 2, SA, OL | Relapsed SCLC | Olaparib | Ongoing |
| NCT03428607 (SUKSES-N2) | Phase 2, SA, OL | Relapsed SCLC | Olaparib + AZD6738 | Ongoing |
| NCT02446704 | Phase 1/2, SA, OL | Relapsed SCLC | Olaparib + Temozolomide | Ongoing |
| NCT02498613 | Phase 2, SA, OL | SCLC | Olaparib + Cediranib maleate | Ongoing |
| NCT02734004 (MEDIOLA) | Phase 1/2, OL, SA | Relapsed SCLC | Olaparib + Durvalumab | Ongoing |
| NCT03672773 (TRIO-US L-07) | Phase 2, SA, OL | Relapsed/refractory ED-SCLC | Talazoparib +Temozolomide | Ongoing |
| NCT04209595 | Phase 1/2, SA, OL | SCLC | Rucaparib + PLX038 | Ongoing |
| NCT03958045 | Phase 2, SA, OL | ED-SCLC | Rucaparib + Nivolumab | Ongoing |
| NCT03227016 | Phase 1/2, SA, OL | SCLC | Veliparib + Topotecan | Ongoing |
| NCT00445198 (132,133) | Phase 1/2, SA, OL, NR | Refractory SCLC | ABT-263 | Completed |
| NCT03080311 | Phase 1, SA, OL | Relapsed SCLC | APG-1252 | Ongoing |
| NCT03387332 | Phase 1, SA, OL | Relapsed SCLC | APG-1252 | Ongoing |
| NCT04210037 | Phase 1, SA, OL | Relapsed/refractory SCLC | APG-1252+ Paclitaxel | Ongoing |
| NCT01970540 (134) | Phase 1, SA, OL | Advanced unresectable SCLC | Lurbinectedin + Doxorubicin | Completed |
| NCT0245497 (135) | Phase 2, SA, OL | Relapsed SCLC | Lurbinectedin | Completed |
| NCT01831089 | Phase 1, SA, OL | Advanced SCLC | Lurbinectedin + Paclitaxel ± Bevacizumab | Completed |
| NCT02566993 (ATLANTIS) | Phase 3, RCT, PA, OL | Refractory SCLC | Arm 1: Lurbinectedin + Doxorubicin | Completed |
| Arm 2: CAV | ||||
| Arm 3: Topotecan | ||||
| NCT04253145 | Phase 1/2, SA, OL | Refractory SCLC | PM01183 + Atezolizumab | Ongoing |
| NCT01901653 (19) | Phase 1/2, SA, OL | Relapsed SCLC | Rova-T | Completed |
| NCT02674568 (TRINITY) (136) | Phase 2, SA, OL | Relapsed/refractory DLL3 SCLC | Rova-T | Completed |
| NCT03033511 (MERU) | Phase 3, RCT, PA, OL, DB | ED-SCLC | Arm 1: Rova-T + Dexamethasone | Terminated |
| Arm 2: Placebo | ||||
| NCT03061812 (TAHOE) | Phase 3, RCT, PA, OL | Platinum-resistant SCLC | Arm 1: Rova-T | Completed |
| Arm 2: Topotecan | ||||
| NCT02819999 | Phase 1, RCT, OL | ED-SCLC | Arm 1: Rova-T | Completed |
| Arm 2: Rova-T + EC1 | ||||
| NCT03392064 | Phase 1, SA, OL | Relapsed/refractory SCLC | AMG 119 | Ongoing |
| NCT03026166 | Phase 1/2, SA, OL, PA | ED-SCLC | Arm 1: Rova-T + Nivolumab Arm 2: Rova-T + Nivolumab + Ipilimumab |
Completed |
| NCT03000257 | Phase 1, OL, Multicenter | Advanced SCLC | Arm 1: ABBV-181 | Ongoing |
| Arm 2: ABBV-181 + Rova-T | ||||
| Arm 3: ABBV-181 + Venetoclax | ||||
| NCT03319940 | Phase 1, RCT, OL | Relapsed/refractory/chemo-sensitive SCLC | Arm 1: AMG 757 | Ongoing |
| Arm 2: AMG 757 + Pembrolizumab | ||||
| NCT02499770 (137) | Phase 1b/2, RCT, PA, DB | Untreated ED-SCLC | Arm 1: Trilaciclib + EC | Completed |
| Arm 2: Placebo + EC | ||||
| NCT03041311 | Phase 2, RCT, PA, DB | Untreated ED-SCLC | Arm 1: Trilaciclib + EC + Atezolizumab | Ongoing |
| Arm 2: Placebo + EC+ Atezolizumab | ||||
| NCT02514447 | Phase 1b/2, RCT, PA, DB | Previously treated ED-SCLC | Arm 1: Trilaciclib + Topotecan | Ongoing |
| Arm 2: Placebo + Topotecan | ||||
| NCT04010357 | Phase 2, SA, OL | Refractory, WT-Rb ED-SCLC | Abemaciclib | Ongoing |
CAV, Cyclophosphamide plus Doxorubicin plus Vincristine; DLL3, Delta-Like Protein 3; DB, double-blind; ED, extensive disease; EC, etoposide plus carboplatin; EC1, etoposide plus cisplatin; EP, etoposide plus either cisplatin or carboplatin; NR, non-randomized; OL, open-label; PA, parallel assignment; RCT, randomized controlled trial; SCLC, small cell lung cancer; SA, single arm; WT-Rb, Rb Wild-Type.